<DOC>
	<DOCNO>NCT00321334</DOCNO>
	<brief_summary>The objective trial determine whether 3 cycle TP ( docetaxel plus cisplatin ) complete operation improve survival compare 3 cycle TP prior complete resection NSCLC .</brief_summary>
	<brief_title>Survival Study Docetaxel Carboplatin Neo-Adjuvant Vs Adjuvant Chemotherapy Early Stage NSLC</brief_title>
	<detailed_description>Non-small-cell lung cancer ( NSCLC ) account approximately 80 % lung cancer diagnose worldwide . Surgical resection offer best chance cure patient diagnose early-stage disease , however , vast majority patient experience eventually relapse metastasis . The rationale neoadjuvant adjuvant chemotherapy early stage NSCLC lie possibility eradicate micro-metastasis disease , appear improve survival reduce occurrence distant metastasis . Meta analysis , CALGB 9633 , JBR 10 ANITA trial show postoperative ( adjuvant ) CT complete resection prolong survival . On hand , Depierre et al conduct trial demonstrate preoperative ( neoadjuvant ) chemotherapy early stage NSCLC appear improve survival . We need head head trial comparing neoadjuvant adjuvant chemotherapy answer treatment model well early stager NSCLC . Based proven activity survival benefit advance NSCLC , docetaxel introduce neoadjuvant therapy , even potential option adjuvant setting . Comparison : 3 cycle TP complete operation compare 3 cycle TP prior complete resection NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically confirm stage IBIIIA nonsmall cell lung cancer patient , without previous chemotherapy , radiotherapy targettherapy ; age 18 75 ; PS ECOC 01 ; Adequate haematological Hepatic renal function ; Expected live long 12 month ; The informed consent sign . Patients Small Cell Lung Cancer ; Already receive prior anticancer treatment ; Pregnant woman ; Uncontrolled diabetes , mental disease ; Hepatic renal function failure ; The investigator believe patient suitable enrol study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>surgery</keyword>
	<keyword>neo-adjuvant</keyword>
	<keyword>adjuvant</keyword>
	<keyword>RCT</keyword>
</DOC>